H. Sinn

COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy

A. Schneeweiss, M. Golatta, J. Heil, 2022, ESMO open.

Pathophysiologic basis of contrast enhancement in breast tumors

G Brix, M V Knopp, G van Kaick, 1999, Journal of magnetic resonance imaging : JMRI.

AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022

M. Lux, P. Fasching, T. Fehm, 2022, Geburtshilfe und Frauenheilkunde.

A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer.

A. Schneeweiss, T. Bauknecht, F. Marmé, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response?

A. Schneeweiss, M. Golatta, G. Rauch, 2016, Annals of Surgical Oncology.

Abstract PD2-07: mRNA signatures predict response to durvalumab therapy in triple negative breast cancer (TNBC)– Results of the translational biomarker programme of the neoadjuvant double-blind placebo controlled GeparNuevo trial

A. Schneeweiss, F. Marmé, S. Loibl, 2019, Poster Discussion Abstracts.